DK0538330T3 - Beta-Alethin-anvendelse til celledyrkning og terapi - Google Patents

Beta-Alethin-anvendelse til celledyrkning og terapi

Info

Publication number
DK0538330T3
DK0538330T3 DK91912761.3T DK91912761T DK0538330T3 DK 0538330 T3 DK0538330 T3 DK 0538330T3 DK 91912761 T DK91912761 T DK 91912761T DK 0538330 T3 DK0538330 T3 DK 0538330T3
Authority
DK
Denmark
Prior art keywords
beta
alethin
therapy
cell culture
alethine
Prior art date
Application number
DK91912761.3T
Other languages
English (en)
Inventor
Galen Daryl Knight
Paul Leslie Mann
Terence Joseph Scallen
Original Assignee
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Mexico filed Critical Univ New Mexico
Application granted granted Critical
Publication of DK0538330T3 publication Critical patent/DK0538330T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK91912761.3T 1990-07-06 1991-07-08 Beta-Alethin-anvendelse til celledyrkning og terapi DK0538330T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54910490A 1990-07-06 1990-07-06
US54910390A 1990-07-06 1990-07-06

Publications (1)

Publication Number Publication Date
DK0538330T3 true DK0538330T3 (da) 1996-02-26

Family

ID=27069009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91912761.3T DK0538330T3 (da) 1990-07-06 1991-07-08 Beta-Alethin-anvendelse til celledyrkning og terapi

Country Status (9)

Country Link
EP (1) EP0538330B1 (da)
JP (1) JP3319597B2 (da)
AT (1) ATE128964T1 (da)
AU (1) AU646875B2 (da)
DE (1) DE69113802T2 (da)
DK (1) DK0538330T3 (da)
ES (1) ES2080954T3 (da)
GR (1) GR3018632T3 (da)
WO (1) WO1992000960A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245561B1 (en) 1990-07-06 2001-06-12 University Of New Mexico β-alethine use in cell culture and therapy
US5643966A (en) * 1990-07-06 1997-07-01 University Of New Mexico β-alethine as anti-tumor agent
DE69131752T2 (de) * 1990-07-06 2000-06-29 University Of New Mexico, Albuquerque Vitalethin und seine anwendung in zellkultur und therapie
WO1994026259A1 (en) * 1993-05-12 1994-11-24 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US6007819A (en) 1995-10-17 1999-12-28 Dovetail Technologies, Inc. Methods of inducing immunity using low molecular weight immune stimulants
JP2002503700A (ja) 1998-02-24 2002-02-05 ドヴェテイル テクノロジー インコーポレイテッド 新規なジスルフィドおよびチオール化合物
US6762174B1 (en) 1998-02-24 2004-07-13 Dovetail Technologies, Inc. Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552765A (en) * 1982-05-14 1985-11-12 Santen Pharmaceutical Co., Ltd. Aletheine derivatives
JPS5973515A (ja) * 1982-10-20 1984-04-25 Santen Pharmaceut Co Ltd 肝障害抑制剤

Also Published As

Publication number Publication date
DE69113802D1 (de) 1995-11-16
EP0538330A4 (en) 1993-07-07
JP3319597B2 (ja) 2002-09-03
EP0538330A1 (en) 1993-04-28
AU8207791A (en) 1992-02-04
JPH05508769A (ja) 1993-12-09
EP0538330B1 (en) 1995-10-11
WO1992000960A1 (en) 1992-01-23
AU646875B2 (en) 1994-03-10
ES2080954T3 (es) 1996-02-16
GR3018632T3 (en) 1996-04-30
DE69113802T2 (de) 1996-05-15
ATE128964T1 (de) 1995-10-15

Similar Documents

Publication Publication Date Title
BR9910251A (pt) Estimulação hematopoiética
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
ZA91574B (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
GR3017535T3 (en) Live vaccines.
DE69905368D1 (en) Oxydiertes thymosin beta 4
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
MY138883A (en) Use of asiatic acid for treatment of cencer
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
PH27214A (en) N-2,3-butadienyl tri and tetraaminoalkane derivatives
ITRM970238A0 (it) Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella terapia di patologie corneali e congiuntivali
ES544664A0 (es) Procedimiento para el diagnostico in vitro del sexo
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
ZA855224B (en) Pyrrol-1-ylphenyldihydropyridazinones,their preparation and their use
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
ATE141510T1 (de) Arzneimittel enthaltend cd14
ES2037053T3 (es) Derivados del acido (met)-acrilico de triisocianatos y su empleo.
BR9911294A (pt) Composição para o tratamento de imuno deficiências e métodos para sua preparação e uso
DK0539525T3 (da) Vitalethein og anvendelse deraf i cellekultur og terapi
ES2112562T3 (es) Nuevo difenilhexeno.
Moises et al. Abstract 30. Interferon production in blood cell cultures of schizophrenic patients
EP0278715A3 (en) Use of human gamma interferon for treatment of basal cell carcinoma